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Abstract Our recent studies have shown that intracellular levels 
of sphingosine, an endogenous PKC inhibitor, increase during 
apoptosis resulting from phorhol ester (PMA)-induced terminal 
differentiation of human myeloid leukemic HL-60 cells, and have 
suggested that sphingosine may function as an endogenous medi- 
ator of apoptosis in these cells IOhta, et al. (1995) Cancer Res. 
55, 691-6971. We report here that apoptosis induced by PMA, 
sphingosine, and NJV-dimethylsphingosine (DMS) was accompa- 
nied by a concomitant decrease of hcl-2 expression in both RNA 
and protein levels in HL-60 cells, while expression of b&X, and 
bax mRNA did not change, and neither sphingosine nor DMS 
induced differentiation of HL-60 cells. In contrast, in apoptotic 
cells induced by pharmaceutical PKC inhibitors H7 or stauro- 
sporine, expression of bcl-2 did not change nor did the intracellu- 
lar sphingosine concentration. These results suggest that sphingo- 
sine may function as an endogenous mediator of apoptotic sigual- 
ing in PMA-induced terminal differentiation of HL-60 cells 
through bcl-2 down-regulation, probably independent from PKC 
inhibition. 
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1. Introduction 
Cellular homeostasis in vertebrates is regulated by cell death 
as well as by cell proliferation [l-3]. Although the mechanism 
that induces and executes apoptosis is poorly understood, it is 
widely accepted that in most cases cell death is controlled by 
a genetic program which is activated in apoptosis. Recent stud- 
ies have partially clarified this genetic control [4,5], and individ- 
ual genes that either promote or inhibit apoptosis have been 
identified. 
In hematopoietic cells, apoptosis can be coupled to terminal 
differentiation of myeloid progenitors [6,7]. It is generally 
thought that hematopoietic survival factors, such as GM-CSF 
or IL-3, can maintain cell survival by inducing the synthesis of 
cellular proteins capable of suppressing apoptosis [8,9]. One 
such protein is the bcl-2 proto-oncogene product. Bcl-2 encodes 
a 26 kDa integral membrane protein that localizes to the outer 
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mitochondria, smooth endoplasmic reticulum, and perinuclear 
envelop, and is known to be a suppressor gene of apoptosis 
[lo-121. Within the myeloid lineage, bcl-2 is expressed in early 
myeloid precursors but is absent in the mature polymorphonu- 
clear leukocytes [I 31. Similarly, bcl-2 gene expression is re- 
pressed during PMA-induced differentiation in promyelocytic 
HL-60 cells [l4]. The correlation between the expression of 
bcl-2 and differentiation suggests that down-regulation of the 
bcl-2 gene may be part of the myeloid maturation pathway, 
however, the mechanism of the bcl-2 down-regulation itself has 
not yet been clarified. In our previous studies, we have reported 
that exogenously added sphingosine induced apoptosis in HL- 
60 cells, and that in HL-60 cells differentiated by phorbol ester 
(PMA) sphingosine concentrations were several folds greater 
than those in the untreated cells [15]. It is of interest to analyze 
how sphingosine, which is known to be an endogenous PKC 
inhibitor, is involved in the mechanisms of induction of differ- 
entiation and apoptosis, since some pharmaceutical PKC inhib- 
itors cause apoptosis without cell differentiation in HL-60 cells 
[16]. Therefore, in this study we examined the effect of PMA 
and exogenously added sphingosine and N, N-dimethylsphingo- 
sine (DMS) on the regulation of apoptosis-related genes such 
as bcl-2, bax, and bcl-X,, and we found a difference in the 
regulation of bcl-2 expression between sphingosine/DMS and 
other PKC inhibitors, suggesting that apoptosis induction by 
sphingosine and DMS is via a mechanism different from PKC 
inhibition. 
2. Materials and methods 
2.1. Cell culture 
Human myeloid leukemia HL-60 cells were purchased from Ameri- 
can Type Culture Collection (ATCC), and maintained in RPM11640 
containing fetal bovine serum, 100 units/ml penicillin, lOOpg/ml strep- 
tomycin, and 2 mM L-glutamate. 
2.2. Analysis of DNA fragmentation 
DNA fragmentation was analyzed by agarose gel electrophoresis. 
HL-60 cells were treated for 6 h at 37°C with one of the following: 
5 nM PMA, 5 PM sphingosine, DMS, C2 ceramide, or sphingosine-l- 
phosphate, 100 nM H7 or 1OOnM staurosporine. All sphingolipids were 
dissolved in 50% ethanol. H7 and staurosporine were dissolved in 
DMSO. DNA was extracted as described previously [15]. Cells were 
harvested. washed, and incubated in 0.5 ml of 50 mM Tris-HCl, pH 8.0, 
containing 1 mM EDTA, 0.25% NP-40, and 0.1% RNase A at 37°C 
for 30 min. Fifty ~1 of 10 mg/ml proteinase K (Boehringer Mannheim, 
Mannheim, Germany) were added, and incubation was continued for 
an additional 30 min. After incubation, 5 pg DNA was applied to each 
lane in 1.5% agarose gel. DNA in gels was visualized under UV light 
after staining with ethidium bromide. 
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2.3. Northern blot analysis 
Total RNA was extracted by using a guanidine isothiocyanate-CsCl, 
procedure as described previously [15]. The following DNA probes 
were used: (a) nt 121 to nt 579 bcl-2 fragment (459 bp), (b) nt 96 to nt 
875 b&X, fragment, (780 bp), (c) nt 1 to nt 323 bax fragment, (323 bp). 
2.4. Western blot unalysis 
After treatment with each agent, 1 x 1Oh cells were washed twice with 
PBS and lysed in 1% Triton X-100,0.15 M NaCl and 10 mM Tris-HCl, 
pH 7.4, with 50 fig/ml PMSF and 2 pg/ml aprotinin at 4°C for 30 min. 
Lysates were centrifuged at 10,000 x g for 10 min, and boiled in SDS 
sample buffer for 5 min before running on a 7.5% SDS-polyacrylamide 
gel. After overnight transfer of SDS-polyacrylamide gel to nitrocellu- 
lose membrane (PVDF, MILLIPORE), blots were blocked in 3% BSA 
for 2 h at room temperature. Rabbit polyclonal antibody to human 
bcl-2 (DAKO, A/S, Denmark) was used at l/l000 dilution in PBS with 
3% BSA for 2 h at room temperature. Horseradish peroxidase-conju- 
gated goat anti-rabbit IgG antibody was incubated with the blot at 
l/4000 dilution in PBS with 3% BSA for 2 h at room temperature. The 
blot was visualized with ECL kit (Amersham). 
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Fig. 1. Panel A. Agarose gel electrophoresis of DNA from cells treated 
with 5 nM PMA for indicated times. DNA was isolated from cells and 
analyzed in 1.5% agarose gel electrophoresis. The marker is Hind111 
digest of A-DNA. Panel B. Agarose gel electrophoresis of DNA from 
cells treated with different agents. HL-60 cells were treated with 5 ,uM 
sphingosine (Sph), 5 ,uM DMS, 5 .uM C2-ceramide, 5 ,uM sphingosine- 
l-phosphate, 100 nM H7, or 100 nM staurosporine for 6 h. DNA was 
isolated from cells and analyzed in 1.5% agarose gel electrophoresis. 
The marker is Hind111 digest of 1 DNA. 
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Fig. 2. Panel A. Effect of PMA, H7 and staurosporine on sphingosine 
concentration in HL-60 cells. HL-60 cells were treated with each agent 
for 6 h. Cellular lipids were extracted and the concentration of sphingo- 
sine was measured as described in section 2. Panel B. Effect of PMA, 
H7, or staurosporine on expression of bcl-2 mRNA. HL-60 cells were 
treated with each agent for the indicated time. Northern blots were 
performed as described in section 2. The B-actin cDNA generated by 
PCR was used as internal control of the RNA amount in each lane as 
described previously [15]. 
2.5. Measurement of sphingosine concentration 
Cells were treated with PMA, H7 or staurosporine, and then lipids 
were extracted from cells. Sphingosine concentrations were measured 
by conversion to N-[‘Hlacetylated sphingosine with [3H]acetic anhy- 
dride as described previously [17]. Radioactive bands were scraped off 
and counted by Beckman scintillation counter (Beckman). 
3. Results and discussion 
Endogenous sphingolipid metabolites such as ceramide and 
sphingosine have been increasingly recognized as lipid media- 
tors of cell growth, differentiation and apoptosis. Sphingosine 
acts as an endogenous regulator of membrane signaling 
through protein kinase C or other unknown mechanisms [18- 
211. We have shown that sphingosine, and N,N-dimethylsphin- 
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Fig. 3. Panel A. Effect of DMS, sphingosine and CZ-ceramide on expression of bcl-2, bax, and bcl-X, mRNA. HL-60 cells were treated with each 
agent at a concentration of 5 PM for indicated time. Northern blots were performed as described in section 2. Panel B. Effect of DMS, sphingosine 
and C2-ceramide on expression of bcl-2 protein. HL-60 cells were treated with each agent at a concentration of 5 PM for the indicated time. Western 
blots were performed as described in section 2. 
gosine, induce apoptosis in HL-60 cells [15] as well as in other 
solid tumor cells [22,23]. However, involvement of sphingosine 
in the mechanism to induce apoptosis in terminal differentia- 
tion of hematopoietic cells has not yet been clarified. 
PMA induces terminal differentiation in HL-60 cells, and as 
a consequence, induces apoptosis with the characteristic pat- 
tern of DNA fragmentation as shown in Fig. 1A. This apopto- 
sis is associated with an increase in intracellular sphingosine 
concentrations and bcl-2 down-regulation. Both 5 ,uM sphingo- 
sine and DMS induced down-regulation of bcl-2 by 80-90% at 
6 h in both mRNA and protein levels (Fig. 3). As shown in Fig. 
2 A and B, sphingosine concentrations in HL-60 cells increased 
3.3-fold after lh incubation with PMA, and bcl-2 expression 
was inhibited with concomitant cell differentiation. H7 and 
staurosporine are known to be pharmaceutical PKC inhibitors 
and can induce apoptosis in HL-60 cells as shown in Fig. 1B. 
However, the apoptotic process is not associated with cell dif- 
ferentiation, increase of intracellular sphingosine concentration 
(Fig. 2A), or bcl-2 down-regulation (Fig. 2B), suggesting that 
the mechanism of apoptosis induced by sphingosine may differ 
from that of other PKC inhibitors. The effect of DMS was 
stronger than that of sphingosine in the induction of apoptosis 
and bcl-2 down-regulation. Both compounds are rapidly taken 
up by cells, but, whereas sphingosine is efficiently converted to 
Sph-l-phosphate and ceramide, DMS is not metabolically con- 
verted into any other compound in most cells [24-261. The 
difference in efficiency of sphingosine vs. DMS may be due to 
their different metabolic fates. Neither ceramide nor sphingo- 
sine-l-phosphate, the initial products of sphingosine, caused 
apoptosis (Fig. 1B) or affected bcl-2 expression (data not 
shown), although high concentrations of the analogue C2-cer- 
amide does induce apoptosis with down-regulation of bcl-2 in 
HL-60 cells [27]. One previous report showed that the PKC- 
inhibitor calphostin C also did not change the expression of 
bcl-2 [16]. 
Down-regulation of bcl-2 is associated with differentiation 
and apoptosis of hematopoietic cells as observed in PMA- 
treated HL-60 cells (Fig. 2B). Although sphingosine inhibited 
bcl-2 expression, it did not induce differentiation of HL-60 
cells. PMA is PKC activator and sphingosine is PKC inhibitor. 
Not only bcl-2 down-regulation but also activation of other 
factors such as PKC are apparently necessary to induce differ- 
entiation in HL-60 cells. These observations suggest that sphin- 
gosine may function as an endogenous inducer of apoptosis in 
differentiated hematopoietic cells through down-regulation of 
bcl-2, but other factors would be involved to differentiate HL- 
60 cells. That various PKC inhibitors have been shown to 
inhibit PMA-induced leukemic cell maturation [28,29] and that 
the induction of apoptosis by H7 or staurosporine was not 
accompanied by cellular differentiation provides indirect evi- 
dence that separate differentiation-dependent and -independ- 
ent pathways of apoptosis may exist and that differentiation- 
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dependent apoptosis will be associated with down-regulation of 
bcl-2. 
The mechanism by which bcl-2 and other bcl-2-related pro- 
teins inhibit apoptosis is poorly understood. Recent evidence 
suggests that bcl-2 may prevent apoptosis through the regula- 
tion of an antioxidant pathway [30]. Bcl-2 appears to be ex- 
pressed as part of an intracellular protein complex. For exam- 
ple, bcl-2 has been shown to interact with at least two cellular 
proteins bax [3 I] and r-Ras p23 [32], although the significance 
of these protein interactions is not well understood. Recently, 
bcl-X, a gene related to bcl-2, has been identified [33]. Alterna- 
tive splicing of bcl-X produces two mRNA: bcl-X, and bcl-Xs, 
the large (L) and small (S) splice forms. Bcl-X, is a functional 
analogue of bcl-2, and inhibits apoptosis upon growth factor 
withdrawal or X-irradiation, whereas overexpression of bcl-X, 
counteracts the effect of bcl-2 in preventing apoptosis [31]. As 
shown in Fig. 3, in contrast to down-regulation of bcl-2 by 
sphingosine and DMS, neither bax nor bcl-X, expression was 
affected during PMA-induced apoptosis or after treatment with 
sphingosine or DMS. 
Together, these results indicate that the regulation of apopto- 
sis within myeloid cells is complex and is modulated by multiple 
proteins, and sphingolipid metabolites. Intracellular sphingo- 
sine may be involved in apoptosis of terminally differentiated 
HL-60 cells through bcl-2 down-regulation. Thus, the metabo- 
lism of sphingolipids, including the generation of sphingosine, 
is likely to be important in regulating cell growth, differentia- 
tion and apoptosis. 
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